CSPC PHARMA (01093): The Phase Ib/II clinical trial of SYS 6090 injection for the treatment of colorectal cancer has officially launched at the first research center in China.

CSPC PHARMA (01093) announced that the SYS 6090 injection combined treatment plan developed by the group for the treatment of colorectal cancer has officially launched at the first research center in China for its phase Ib/II clinical trial (SYS 6090-008). The product is classified as a Class 1 therapeutic biological product and is a recombinant fully human anti-programmed cell death protein 1 (PD-1) fusion protein that incorporates interleukin-15 (IL-15). It targets PD-1 positive tumor-infiltrating immune cells through its left arm, blocking the immunosuppressive function caused by the interaction between PD-1 and programmed death ligand 1 (PD-L1). Meanwhile, through its right arm, it binds to IL-15 receptors, activating downstream signaling pathways that further promote the activation and proliferation of relevant immune cells. Preclinical study results have shown that this product significantly inhibits tumor growth, has good safety and tolerability, and demonstrates higher efficacy compared to other PD-1 monoclonal antibodies and IL-15 drugs. Previously, the group received the clinical trial approval notice from the National Medical Products Administration of the Peoples Republic of China for this product in March 2026 and initiated the SYS 6090-008 clinical trial following the approval. The approved clinical trial is an open-label, multicenter phase Ib/II study aimed at evaluating the safety, tolerability, and efficacy of this combination treatment plan in colorectal cancer participants. The group will continue to advance this product's combination treatment in a confirmatory phase III clinical trial based on the outcomes of this research, further validating the clinical value of this combination treatment plan. Currently, the participant recruitment and screening for the SYS 6090-008 study are actively underway.